Event Date/Time
Location
EQuad J Wing
J223
J223
Series/Event Type
MAE Departmental Seminars
Image
Dr. Redjal is the Director of Neurosurgical Oncology at the Capital Institute for Neuroscience at Capital Health and will discuss issues with current technologies for intraoperative neuronavigation, fluorescence-guided tumor surgery, problems with current tumor models, and more. This will be a fantastic introduction to a difficult, delicate, and tool-driven aspect of medicine that could benefit from new technologies.
Speaker Bio
Dr. Navid Redjal, director of Neurosurgical Oncology, is a board certified, Harvard trained neurosurgeon with extensive research and clinical background in neuro-oncology. He has been involved in significant translational brain cancer research and neuro-oncology clinical trials with research fellowships at the Dana-Farber Cancer Institute and Massachusetts General Hospital.
Dr. Redjal graduated from Harvard Medical School with honors, specifically completing the Harvard-MIT Health Sciences and Technology Society curriculum with research thesis focusing on targeted therapeutics for brain cancer. After completing medical school, he did his residency at the Massachusetts General Hospital/Harvard neurosurgery program where he also completed a stereotactic proton radiosurgery fellowship. He is board certified in neurological surgery and a diplomate of the American Board of Neurological Surgery. He is also a Fellow of American Association of Neurological Surgeons (FAANS).
Following his residency, Dr. Redjal joined the faculty at Harvard Medical School as an instructor in surgery while also serving as an attending neurosurgeon at Massachusetts General Hospital (MGH), a teaching hospital of Harvard Medical School. After his time at MGH, Dr. Redjal joined Kaiser Permanente in Los Angeles as an attending neurosurgeon with focus in neuro-oncology and worked with neuro-oncologists to advance participation in brain cancer clinical trials.
He specializes in complex brain surgery including awake surgery, language and motor mapping, minimally invasive neuro-endoscopic surgery utilizing detailed MRI-based neuro-navigation with diffuse tensor imaging and intraoperative ultrasound. He also uses the CyberKnife® System in collaboration with radiation oncologists to treat a variety of brain and spine tumors.
Dr. Redjal has conducted significant translational research in targeted local therapy for brain cancer and has been published in a number of medical journals devoted to neurosurgery and cancer research. He has been involved with Congress of Neurologic Surgeons glioma guidelines committee and has coauthored treatment guidelines for glioblastoma multiforme (GBM) and low grade gliomas. He currently leads the weekly Neuro-Oncology Multi-disciplinary Tumor Board at the Capital Health Cancer Center.
Dr. Redjal is a member of the American Association of Neurological Surgeons, the Congress of Neurological Surgeons, the Society for Neuro-Oncology, and a number of other professional societies.
Dr. Redjal graduated from Harvard Medical School with honors, specifically completing the Harvard-MIT Health Sciences and Technology Society curriculum with research thesis focusing on targeted therapeutics for brain cancer. After completing medical school, he did his residency at the Massachusetts General Hospital/Harvard neurosurgery program where he also completed a stereotactic proton radiosurgery fellowship. He is board certified in neurological surgery and a diplomate of the American Board of Neurological Surgery. He is also a Fellow of American Association of Neurological Surgeons (FAANS).
Following his residency, Dr. Redjal joined the faculty at Harvard Medical School as an instructor in surgery while also serving as an attending neurosurgeon at Massachusetts General Hospital (MGH), a teaching hospital of Harvard Medical School. After his time at MGH, Dr. Redjal joined Kaiser Permanente in Los Angeles as an attending neurosurgeon with focus in neuro-oncology and worked with neuro-oncologists to advance participation in brain cancer clinical trials.
He specializes in complex brain surgery including awake surgery, language and motor mapping, minimally invasive neuro-endoscopic surgery utilizing detailed MRI-based neuro-navigation with diffuse tensor imaging and intraoperative ultrasound. He also uses the CyberKnife® System in collaboration with radiation oncologists to treat a variety of brain and spine tumors.
Dr. Redjal has conducted significant translational research in targeted local therapy for brain cancer and has been published in a number of medical journals devoted to neurosurgery and cancer research. He has been involved with Congress of Neurologic Surgeons glioma guidelines committee and has coauthored treatment guidelines for glioblastoma multiforme (GBM) and low grade gliomas. He currently leads the weekly Neuro-Oncology Multi-disciplinary Tumor Board at the Capital Health Cancer Center.
Dr. Redjal is a member of the American Association of Neurological Surgeons, the Congress of Neurological Surgeons, the Society for Neuro-Oncology, and a number of other professional societies.